![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Verstraete, H Bounameaux, F de Cock, F Van de Werf and D Collen
The pharmacokinetics of recombinant human tissue-type plasminogen activator (rt-PA) were studied in 20 subjects during and after its i.v. infusion at three different rates (5.6, 8.3, and 10 micrograms/kg/min). Steady-state plasma concentrations of 0.9 to 1.6 micrograms/ml were reached. The plasma disappearance curves of rt-PA (both antigen and activity) after cessation of infusion were approximated by a sum of two exponential terms and the turnover of rt-PA was represented by a two- compartment mammillary model with peripheral (liver) elimination. The fractional efflux rate constant from the central compartment was 0.10 per min and the fractional catabolic rate constant about 0.02 per min. After cessation of infusion the initial half-life of the drug in plasma was 6 min. Fibrinogen levels were measured by a clotting rate assay and by sodium sulfite precipitation. Infusion of rt-PA at 10 micrograms/kg/min for 30 min did not cause systemic fibrinogen breakdown. Infusion of 5.6 micrograms/kg/min for 90 min was associated with a decrease of fibrinogen to 62% of the preinfusion value (4.5 g/l) as measured with the clotting rate assay, but only 2% was recovered as incoagulable fibrinogen-fibrin degradation products. Infusion of 8.3 micrograms/kg/min for 90 min resulted in a decrease of fibrinogen to 45% of the preinfusion level (2.5 g/l) and generation of 8.5% fibrinogen-fibrin degradation products. Fibrinogen assays with the sodium sulfite method showed a much less extensive decrease of fibrinogen. This extent of systemic fibrinolytic activation and fibrinogen breakdown at high infusion rates and prolonged durations is compatible with that anticipated from the kinetic parameters of the activation of plasminogen by rt-PA.
This article has been cited by other articles:
|
|
 |
|
  D. M. Hermann and C. M. Matter Tissue Plasminogen Activator Induced Reperfusion Injury After Stroke Revisited Circulation, July 24, 2007; 116(4): 363 - 365. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Danielyan, B.-S. Ding, C. Gottstein, D. B. Cines, and V. R. Muzykantov Delivery of Anti-Platelet-Endothelial Cell Adhesion Molecule Single-Chain Variable Fragment-Urokinase Fusion Protein to the Cerebral Vasculature Lyses Arterial Clots and Attenuates Postischemic Brain Edema J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 947 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ganguly, J.-C. Murciano, R. Westrick, J. Leferovich, D. B. Cines, and V. R. Muzykantov The Glycocalyx Protects Erythrocyte-Bound Tissue-Type Plasminogen Activator from Enzymatic Inhibition J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 158 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Komoriya, Y. Kato, Y. Hayashi, K. Ohsuye, R. Nishigaki, and Y. Sugiyama Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents Drug Metab. Dispos., March 1, 2007; 35(3): 469 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Stief, A. Richter, R. Bunder, B. Maisch, and H. Renz Monitoring of Plasmin and Plasminogen Activator Activity in Blood of Patients under Fibrinolytic Treatment by Reteplase Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 213 - 218. [Abstract] [PDF]
|
|
|
|
|
|
K. Ganguly, T. Krasik, S. Medinilla, K. Bdeir, D. B. Cines, V. R. Muzykantov, and J. C. Murciano Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1106 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kilic, M. Bahr, and D. M. Hermann Effects of Recombinant Tissue Plasminogen Activator After Intraluminal Thread Occlusion in Mice: Role of Hemodynamic Alterations Stroke, November 1, 2001; 32(11): 2641 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Waugh, M. Kattash, J. Li, E. Yuksel, M. D. Kuo, M. Lussier, A. B. Weinfeld, R. Saxena, E. D. Rabinovsky, S. Thung, et al. Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model PNAS, February 2, 1999; 96(3): 1065 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Thomaseth and B. Boniollo Simulation of Plasmatic Enzyme Reactions During Thrombolytic Therapy With Recombinant Tissue-Type Plasminogen Activator: from In Vitro Knowledge To New Assumptions In Vivo SIMULATION, April 1, 1996; 66(4): 219 - 228. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
